• Clinical and Experimental Pediatrics
• /
• 제60권3호
• /
• pp.64-69
• /
• 2017

Purpose: The goal of nutritional support for very-low-birth-weight (VLBW) infants from birth to term is to match the in utero growth rates; however, this is rarely achieved. Methods: We evaluated postdischarge growth patterns and growth failure in 81 Korean VLBW infants through a retrospective study. Weight and height were measured and calculated based on age percentile distribution every 3 months until age 24 months. Growth failure was defined as weight and height below the 10th percentile at 24 months. For the subgroup analysis, small-for-gestational age (SGA) and extremely low birth weight (ELBW) infants were evaluated. The growth patterns based on the Korean, World Health Organization (WHO), or Centers for Disease Control and Prevention (CDC) standard were serially compared over time. Results: At postconception age (PCA) 40 weeks, 47 (58%) and 45 infants (55%) showed growth failure in terms of weight and height, respectively. At PCA 24 months, 20 infants (24%) showed growth failure for weight and 14 (18%) for height. Growth failure rates were higher for the SGA infants than for the appropriate-weight-for-gestational age infants at PCA 24 months (P=0.045 for weight and P=0.038 for height). Growth failure rates were higher for the ELBW infants than for the non-ELBW infants at PCA 24 months (P<0.001 for weight and P=0.003 for height). Significant differences were found among the WHO, CDC, and Korean standards (P<0.001). Conclusion: Advancements in neonatal care have improved the catch-up growth of VLBW infants, but this is insufficient. Careful observation and aggressive interventions, especially in SGA and ELBW infants, are needed.

• Clinical and Experimental Pediatrics
• /
• 제57권9호
• /
• pp.379-383
• /
• 2014

Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. GH treatment at a dose of $35-70{\mu}g/kg/day$ should be considered for those with very marked growth retardation, as these patients require rapid catch-up growth. Factors associated with response to GH treatment during the initial 2-3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. Adverse events due to GH treatment are no more common in the SGA population than in other conditions treated with GH. Early surveillance in growth clinics is strongly recommended for children born SGA who have not caught up. Although high dose of up to 0.067 mg/kg/day are relatively safe for short children with growth failure, clinicians need to remain aware of long-term mortality and morbidity after GH treatment.

• Journal of Yeungnam Medical Science
• /
• 제40권1호
• /
• pp.30-36
• /
• 2023

Background: Congenital hypothyroidism (CH) is the leading cause of preventable physical and intellectual disabilities. This study aimed to assess the incidence and clinical characteristics of CH in newborns. Methods: We retrospectively reviewed the medical records of all newborns delivered at the Pusan National University Hospital between January 2011 and March 2021. The incidence of CH was compared according to gestational age, birth weight, and small for gestational age (SGA). The patients aged ≥3 years who could not maintain normal thyroid function and required levothyroxine treatment were diagnosed with permanent CH. Logistic regression analysis was performed to compare CH risks. Results: Of 3,722 newborns, 40 were diagnosed with CH (1.07%). Gestational age and birth weight were significantly associated with CH incidence. The odds ratios (ORs) of CH in infants delivered at 32-37, 28-31, and <28 weeks were 2.568 (95% confidence interval [CI], 1.141-5.778), 5.917 (95% CI, 2.264-15.464), and 7.441 (95% CI, 2.617-21.159) times higher, respectively, than those delivered at term. The ORs of CH in infants weighing 1,500-2,499 g, 1,000-1,499 g, and <1,000 g were 4.664 (95% CI, 1.928-11.279), 11.076 (95% CI, 4.089-29.999), and 12.544 (95% CI, 4.350-36.176) times greater, respectively, than those in infants weighing ≥2,500 g. The OR of CH was 6.795 (95% CI, 3.553-13.692) times greater in SGA than in non-SGA infants. Conclusion: The CH incidence in South Korea has increased significantly compared with that in the past. Gestational age, birth weight, and SGA were significantly associated with CH incidence.

• 한국인구학
• /
• 제35권1호
• /
• pp.131-149
• /
• 2012

본 연구는 2000년 초반과 후반 우리나라의 출산결과와 영아사망에 대한 부모의 사회경제적 지위의 영향력 변화를 파악하고자 하였다. 이를 위해 통계청의 2001-2003년(T1), 2006-2008년(T2) 출생통계와 사망원인통계가 연계된 자료를 활용하였다. 출산결과는 정상아, 부당경량아, 부당중량아, 자궁내발육부전으로 분류하였으며, 영아사망은 생후 1년 이내 사망으로 정의하였다. 자료의 제약으로 인해 부모의 사회경제적 지위는 학력과 직종으로 국한하였다. 분석결과, 불량한 출산결과인 부당경량아와 자궁내발육부전 출생아의 영아사망 위험은 T1 보다 T2에 상대적으로 증가하였다. 이는 미숙아(재태연령 37주 미만), 저체중아(출생 시 체중 2,500g 미만) 중에서도 더 빨리, 더 작게 태어나는 출생아가 최근 증가함으로써 인구의 질이 더욱 악화되었음을 의미한다. 게다가 T1 대비 T2의 영아사망에 대한 모 연령이 지닌 영향력은 사라진 대신 부모의 사회경제적 지위가 지닌 영향력은 증가하여, 궁극적으로 사회계층 간 영아사망 불평등이 심화되고 있음을 의미한다. 부모의 사회경제적 지위에 따른 출산결과와 영아사망의 격차가 향후 어떻게 전개될지에 대한 지속적인 연구가 필요하다.

• Clinical and Experimental Pediatrics
• /
• 제59권1호
• /
• pp.1-7
• /
• 2016

Infants born small for gestational age (SGA) are at increased risk of perinatal morbidity, persistent short stature, and metabolic alterations in later life. Recent studies have focused on the association between birth weight (BW) and later body composition. Some reports suggest that fetal nutrition, as reflected by BW, may have an inverse programing effect on abdominal adiposity later in life. This inverse association between BW and abdominal adiposity in adults may contribute to insulin resistance. Rapid weight gain during infancy in SGA children seemed to be associated with increased fat mass rather than lean mass. Early catch-up growth after SGA birth rather than SGA itself has been noted as a cardiovascular risk factor in later life. Children who are born SGA also have a predisposition to accumulation of fat mass, particularly intra-abdominal fat. It is not yet clear whether this predisposition is due to low BW itself, rapid postnatal catch-up growth, or a combination of both. In this report, we review the published literature on central fat accumulation and metabolic consequences of being SGA, as well as the currently popular research area of SGA, including growth aspects.

• Clinical and Experimental Pediatrics
• /
• 제50권10호
• /
• pp.954-958
• /
• 2007

목 적 : 본원에서 출생한 미숙아들을 대상으로 하여 이들 미숙아들 중에서 부당 경량아 출생과 관련이 있는 요인들에 대해 알아보고자 본 연구를 시행하였다. 방 법 : 2000년 1월부터 2006년 8월까지 출생한 재태 연령 26주 이상 35주 이하의 미숙아 1,010명을 대상으로 하였으며 이들과 이들의 모체의 의무기록을 후향적으로 조사하여 재태 연령, 출생 체중, 성별, 출생 순위, 산모의 나이 및 이전 유산 횟수 등에 관한 자료들을 수집하였고 부당 경량아 출생과 관련이 있는 요인들을 비교 분석하였다. 결 과 : 본 연구에서 미숙아들 중에서 여아에서 남아보다 부당 경량아 출생이 더 많은 것으로 나타났으며(P=0.042) 또한 산모의 나이가 20세 미만이거나 35세 이상인 경우에 부당 경량아 출생이 더 많은 것으로 나타났다(P=0.041). 미숙아의 출생 순위나 산모의 이전 유산 경력은 부당 경량아 출생과 통계학적인 관련성이 없는 것으로 나타났다(P=0.228, P=0.129). 결 론 : 출생 체중과 미숙아의 생존율과의 관련성을 생각해 보면 산모의 나이가 미숙아의 생존율과 관련이 있는 것으로 생각된다. 10대 임신을 줄이고 산모가 고령이 되기 전에 출산을 할 수 있도록 여러 사회적, 정책적인 뒷받침이 이루어진다면 미숙아들의 생존율을 높이고 더 나아가 건강한 정상 신생아 분만에도 큰 도움이 되리라 생각된다.

• Child Health Nursing Research
• /
• 제27권4호
• /
• pp.317-327
• /
• 2021

Purpose: This study aimed to identify small for gestational age (SGA) infants' growth patterns, nutritional status, and associated factors. Methods: This prospective cohort study was conducted at primary-care child health clinics in Greater Kuala Lumpur, Malaysia. The sample consisted of infants who fulfilled the criteria and were born in 2019. The anthropometric data of infants were assessed at birth and at 1, 3, 6, 9, and 12 months. Results: A total of 328 infants were analysed. In total, 27.7%(n=91) of the subjects were SGA infants, and 237 of them were not. Significant differences in the median weight-for-age and length-for-age z-scores were observed between SGA and non-SGA infants at birth, 1 month, 6 months, and 12 months. There was a significant difference between the growth patterns of SGA and non-SGA infants. Birth weight and sex significantly predicted the nutritional status(stunting and underweight) of SGA infants during their first year of life. Conclusion: SGA infants can catch up to achieve normal growth during their first year of life. Even though the nutritional status of SGA infants trends worse than non-SGA infants, adequate infant birth weight monitoring and an emphasis on nutritional advice are crucial for maintaining well-being.

• 한국콘텐츠학회논문지
• /
• 제12권1호
• /
• pp.346-352
• /
• 2012

2010년 1월에서 2010년 12월까지 경기도 광명 소재 산부인과에서 초진에서부터 분만까지 동일 병원에서 실시한 산모 중 37주 이후에 정상 분만한 141명(비직업인군 73명과 직업군 68명)을 대상으로 태아, 신생아체중 및 분만방법을 산모의 직업여부에 따라 비교 분석하여 보았으며, 다음과 같은 결과를 얻었다. 1. 임신후 37주 기간의 산모체중 및 평균임신기간은 통계적인 차이는 없었다. 2. 37주시 태아체중은 비직업군은 평균 $2.90{\pm}0.27kg$, 저체중아 비율은 2.75%, 직업군에서는 평균 $2.76{\pm}0.28kg$, 저체중아 비율은 10.3%로 나타나 비직업군에서 37주 태아체중이 유의하게 높게 나타났다(p<0.05). 3. 신생아체중은 비직업군은 평균 $3.42{\pm}0.43kg$, 직업군은 $3.18{\pm}0.35kg$으로 비직업군의 신생아체중이 유의하게 높게 나타났다(p<0.05). 4. 분만방법은 비직업군에서 제왕절개수술이 32.9%, 직업군에서는 16.2%로 비직업군에서 통계적으로 유의하게 많게 나타났다(p<0.05).

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제23권4호
• /
• pp.366-376
• /
• 2020

Purpose: To assess the association between birth weight and the development of functional gastrointestinal disorders (FGIDs) in the first year of life. Methods: This is a secondary analysis of a prospective cohort multicenter study including neonates, consecutively enrolled at birth, and followed up for one year. At birth all infants were classified by birth weight as extremely low (ELBW), very low, or low when <1,000, <1,500, and <2,500 g, respectively, and by birth weight for gestational age as appropriate (AGA, weight in the 10-90th percentile), small (SGA, weight <10th percentile), and large (LGA, weight >90th percentile) for gestational age. FGIDs were classified according to the Rome III criteria and assessed at 1, 3, 6, and 12 months of life. Results: Among 1,152 newborns enrolled, 934 (81.1%) completed the study: 302 (32.3%) were preterm, 35 (3.7%) were ELBW, 104 (11.1%) were SGA, 782 (83.7%) were AGA, and 48 (5.1%) were LGA infants. Overall, throughout the first year of life, 718 (76.9%) reported at least one FGID. The proportion of infants presenting with at least one FGID was significantly higher in ELBW (97%) compared to LBW (74%) (p=0.01) and in LGA (85.4%) and SGA (85.6%) compared to AGA (75.2%) (p=0.0001). On multivariate analysis, SGA was significantly associated with infantile colic. Conclusion: We observed an increased risk of FGIDs in ELBW, SGA, and LGA neonates. Our results suggest that prenatal factors determining birth weight may influence the development of FGIDs in infants. Understanding the role of all potential risk factors may provide new insights and targeted approaches for FGIDs.

• Journal of Interdisciplinary Genomics
• /
• 제5권2호
• /
• pp.18-23
• /
• 2023

Conventional evaluation method for identifying the organic cause of short stature has a low detection rate. If an infant who is small for gestational age manifests postnatal growth deterioration, triangular face, relative macrocephaly, and protruding forehead, a genetic testing of IGF2, H19, GRB10, MEST, CDKN1, CUL7, OBSL1, and CCDC9 should be considered to determine the presence of Silver-Russell syndrome and 3-M syndrome. If a short patient with prenatal growth failure also exhibits postnatal growth failure, microcephaly, low IGF-1 levels, sensorineural deafness, or impaired intellectual development, genetic testing of IGF1 and IGFALS should be conducted. Furthermore, genetic testing of GH1, GHRHR, HESX1, SOX3, PROP1, POU1F1, and LHX3 should be considered if patients with isolated growth hormone deficiency have short stature below -3 standard deviation score, barely detectable serum growth hormone concentration, and other deficiencies of anterior pituitary hormone. In short patients with height SDS <-3 and high growth hormone levels, genetic testing should be considered to identify GHR mutations. Lastly, when severe short patients (height z score <-3) exhibit high levels of prolactin and recurrent pulmonary infection, genetic testing should be conducted to identify STAT5B mutations.